Shares of Sarepta Therapeutics Inc slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed its decision on a panel meeting.
slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed its decision on a panel meeting.
"This change adds drama to the equation," said Baird analyst Brian Skorney. The FDA's inconsistency may be a signal of more internal debate than previously anticipated, he said.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meetingSarepta Therapeutics Inc. shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech company and said...
Baca lebih lajut »
First Republic stock drops despite $30B infusion in chaotic weekShares of First Republic stock dropped by as much as 30% Friday, with shares selling at just over $25 apiece at one point.
Baca lebih lajut »
FDA panel to meet Thursday to discuss full approval of PaxlovidA Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill...
Baca lebih lajut »
No clear association between Paxlovid and COVID-19 rebound, FDA saysAn FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Baca lebih lajut »
Abortion pill ruling looms over FDA's drug approval processA federal judge in Texas is poised to rule 'as soon as possible' on whether to suspend the FDA's approval of a widely-used abortion pill and potentially reverse the agency's authority on drug regulation for the first time.
Baca lebih lajut »
Texas judge hears arguments in challenge to FDA’s approval of abortion drugA federal judge in Texas heard arguments but did not rule Wednesday on whether to block the Food and Drug Administration’s approval of a pregnancy-termination drug, a case viewed as the most significant legal battleground on abortion since the fall of Roe v. Wade.
Baca lebih lajut »